Two Sigma Advisers
SPRY icon

Two Sigma Advisers’s ARS Pharmaceuticals SPRY Stock Holding History

Two Sigma Advisers’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-41,200
Closed -$719K – 2616
2025
Q2 		$719K Buy
41,200
+300
+0.7% +$4.33K ﹤0.01% 1590
2025
Q1 		$515K Sell
40,900
-100
-0.2% -$1.2K ﹤0.01% 1765
2024
Q4 		$433K Sell
41,000
-400
-1% -$5.6K ﹤0.01% 1836
2024
Q3 		$600K Buy
41,400
+17,100
+70% +$203K ﹤0.01% 1625
2024
Q2 		$207K Buy
+24,300
New +$216K ﹤0.01% 2203
2023
Q3 		– Sell
-226,800
Closed -$1.52M – 2563
2023
Q2 		$1.52M Buy
226,800
+6,000
+3% +$40K ﹤0.01% 1342
2023
Q1 		$1.44M Sell
220,800
-23,300
-10% -$179K ﹤0.01% 1450
2022
Q4 		$2.08M Sell
244,100
-25,700
-10% -$167K 0.01% 1222
2022
Q3 		$1.43M Sell
269,800
-156,900
-37% -$773K ﹤0.01% 1350
2022
Q2 		$1.81M Buy
426,700
+55,900
+15% +$195K 0.01% 1270
2022
Q1 		$1.3M Buy
370,800
+144,100
+64% +$627K ﹤0.01% 1488
2021
Q4 		$1.51M Buy
226,700
+189,100
+503% +$1.54M ﹤0.01% 1325
2021
Q3 		$375K Buy
+37,600
New +$927K ﹤0.01% 2030

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Two Sigma Advisers's SPRY Position: Q3 2025 in Review

Two Sigma Advisers sold out of ARS Pharmaceuticals (SPRY) in Q3 2025, closing a stake of 41,200 shares — an estimated $719K sold.

Two Sigma Advisers first reported a position in SPRY in Q3 2021 and held it in 13 quarters. The position peaked at $2.08M in Q4 2022. 188 funds tracked by Wall St. Rank hold SPRY as of Q3 2025.

  • Two Sigma Advisers reported no remaining ARS Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Two Sigma Advisers sold 41,200 ARS Pharmaceuticals shares in Q3 2025, an estimated $719K.
  • Two Sigma Advisers first reported a position in ARS Pharmaceuticals in Q3 2021 and held it in 13 quarters.
  • Two Sigma Advisers's ARS Pharmaceuticals position peaked at $2.08M in Q4 2022.
  • 188 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2025.

Based on Two Sigma Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.